new

Get trending papers in your email inbox!

Subscribe

Daily Papers

byAK and the research community

Dec 25

FlowDock: Geometric Flow Matching for Generative Protein-Ligand Docking and Affinity Prediction

Powerful generative AI models of protein-ligand structure have recently been proposed, but few of these methods support both flexible protein-ligand docking and affinity estimation. Of those that do, none can directly model multiple binding ligands concurrently or have been rigorously benchmarked on pharmacologically relevant drug targets, hindering their widespread adoption in drug discovery efforts. In this work, we propose FlowDock, the first deep geometric generative model based on conditional flow matching that learns to directly map unbound (apo) structures to their bound (holo) counterparts for an arbitrary number of binding ligands. Furthermore, FlowDock provides predicted structural confidence scores and binding affinity values with each of its generated protein-ligand complex structures, enabling fast virtual screening of new (multi-ligand) drug targets. For the well-known PoseBusters Benchmark dataset, FlowDock outperforms single-sequence AlphaFold 3 with a 51% blind docking success rate using unbound (apo) protein input structures and without any information derived from multiple sequence alignments, and for the challenging new DockGen-E dataset, FlowDock outperforms single-sequence AlphaFold 3 and matches single-sequence Chai-1 for binding pocket generalization. Additionally, in the ligand category of the 16th community-wide Critical Assessment of Techniques for Structure Prediction (CASP16), FlowDock ranked among the top-5 methods for pharmacological binding affinity estimation across 140 protein-ligand complexes, demonstrating the efficacy of its learned representations in virtual screening. Source code, data, and pre-trained models are available at https://github.com/BioinfoMachineLearning/FlowDock.

  • 2 authors
·
Dec 14, 2024

OneChart: Purify the Chart Structural Extraction via One Auxiliary Token

Chart parsing poses a significant challenge due to the diversity of styles, values, texts, and so forth. Even advanced large vision-language models (LVLMs) with billions of parameters struggle to handle such tasks satisfactorily. To address this, we propose OneChart: a reliable agent specifically devised for the structural extraction of chart information. Similar to popular LVLMs, OneChart incorporates an autoregressive main body. Uniquely, to enhance the reliability of the numerical parts of the output, we introduce an auxiliary token placed at the beginning of the total tokens along with an additional decoder. The numerically optimized (auxiliary) token allows subsequent tokens for chart parsing to capture enhanced numerical features through causal attention. Furthermore, with the aid of the auxiliary token, we have devised a self-evaluation mechanism that enables the model to gauge the reliability of its chart parsing results by providing confidence scores for the generated content. Compared to current state-of-the-art (SOTA) chart parsing models, e.g., DePlot, ChartVLM, ChartAst, OneChart significantly outperforms in Average Precision (AP) for chart structural extraction across multiple public benchmarks, despite enjoying only 0.2 billion parameters. Moreover, as a chart parsing agent, it also brings 10%+ accuracy gains for the popular LVLM (LLaVA-1.6) in the downstream ChartQA benchmark.

  • 9 authors
·
Apr 15, 2024

ReviewGuard: Enhancing Deficient Peer Review Detection via LLM-Driven Data Augmentation

Peer review serves as the gatekeeper of science, yet the surge in submissions and widespread adoption of large language models (LLMs) in scholarly evaluation present unprecedented challenges. Recent work has focused on using LLMs to improve review efficiency or generate insightful review content. However, unchecked deficient reviews from both human experts and AI systems threaten to systematically undermine the peer review ecosystem and compromise academic integrity. To address this critical issue, we introduce ReviewGuard, an automated system for detecting and categorizing deficient reviews. ReviewGuard employs a comprehensive four-stage LLM-driven framework that: (1) collects ICLR and NeurIPS papers with their corresponding reviews from OpenReview; (2) annotates review types using GPT-4.1 with human validation; (3) addresses class imbalance and data scarcity through LLM-driven synthetic data augmentation, producing a final corpus of 6,634 papers, 24,657 real reviews, and 46,438 synthetic reviews; and (4) fine-tunes both encoder-based models and open source LLMs. We perform comprehensive feature analysis of the structure and quality of the review text. Compared to sufficient reviews, deficient reviews demonstrate lower rating scores, higher self-reported confidence, reduced structural complexity, and a higher proportion of negative sentiment. AI-generated text detection reveals that, since ChatGPT's emergence, AI-generated reviews have increased dramatically. In the evaluation of deficient review detection models, mixed training with synthetic and real review data provides substantial enhancements to recall and F1 scores on the binary task. This study presents the first LLM-driven system for detecting deficient peer reviews, providing evidence to inform AI governance in peer review while offering valuable insights into human-AI collaboration to maintain academic integrity.

  • 9 authors
·
Oct 18

DrugReasoner: Interpretable Drug Approval Prediction with a Reasoning-augmented Language Model

Drug discovery is a complex and resource-intensive process, making early prediction of approval outcomes critical for optimizing research investments. While classical machine learning and deep learning methods have shown promise in drug approval prediction, their limited interpretability constraints their impact. Here, we present DrugReasoner, a reasoning-based large language model (LLM) built on the LLaMA architecture and fine-tuned with group relative policy optimization (GRPO) to predict the likelihood of small-molecule approval. DrugReasoner integrates molecular descriptors with comparative reasoning against structurally similar approved and unapproved compounds, generating predictions alongside step-by-step rationales and confidence scores. DrugReasoner achieved robust performance with an AUC of 0.732 and an F1 score of 0.729 on the validation set and 0.725 and 0.718 on the test set, respectively. These results outperformed conventional baselines, including logistic regression, support vector machine, and k-nearest neighbors and had competitive performance relative to XGBoost. On an external independent dataset, DrugReasoner outperformed both baseline and the recently developed ChemAP model, achieving an AUC of 0.728 and an F1-score of 0.774, while maintaining high precision and balanced sensitivity, demonstrating robustness in real-world scenarios. These findings demonstrate that DrugReasoner not only delivers competitive predictive accuracy but also enhances transparency through its reasoning outputs, thereby addressing a key bottleneck in AI-assisted drug discovery. This study highlights the potential of reasoning-augmented LLMs as interpretable and effective tools for pharmaceutical decision-making.

  • 6 authors
·
Aug 25 2